[Study of nomifensine in the treatment of depressive states (author's transl)].
The nomifensine antidepressant activity, tolerance and rapidity of action have been studied by 95 psychiatrists in 498 patients during a 4 week open treatment. A 12 items evaluation scale allowed the estimation of the efficacy of the drug in depressed patients distributed to 4 classes of diagnosis: reactional, neurotic, endogenous and other type of depression. Side effects and rapidity of action of the treatment have been recorded during the whole treatment. Nomifensine's antidepressant activity was already observed after one week of treatment: the global scores were significantly diminished at this time in the 4 types of depressive patients. Items such as loss of interest, depressive mood and idea of suicide have been strongly ameliorated and have put in evidence the therapeutic profile and the security of use of this drug The significant and rapid decrease of severity of the symptoms as well as the excellent tolerance of the drug support the psychiatrists' judgement of satisfaction and confirm nomifensine as a major antidepressant, well tolerated and with a rapid onset of action.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009627:Nomifensine / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D007546:Isoquinolines; D009627:Nomifensine
Etude de la nomifensine dans le traitement des états dépressifs.